TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01879202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate modified release
Description: Ritalin 20mg once daily within the first week, Ritalin 30mg once daily within the second week and afterwards Ritalin 40mg will be taken once daily throughout the remaining active treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Study medication will be taken once daily. Patients will take 20mg of study medication within the first week, 30mg within the second week and afterwards 40mg of study medication throughout the remaining active study period.
Study: NCT03147807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: betaLACTA® rapid diagnostic test
Description: Since ≥1 bacteriological sample(s) from ICU patients empirically treated with carbapenems (i.e. respiratory sample such as quantitative tracheobronchial aspirate with available volume ≥1 mL; urinary sample such as single catheter urine specimen; or blood culture) is positive for ≥2 GNB/field on direct examination, empirical carbapenem will be adapted: 1) early, since the second dose, according to the results of the betaLACTA® rapid diagnostic test (BLT) in the intervention arm (i.e. de-escalation to cefepim or to ceftazidim+amikacin in case of negativity, and carbapenem continuation in case of positivity); or 2) after 48-72h according to the results of the antibiotic susceptibility test in the control arm.
Study: NCT03191825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endre: a digital smoking cessation counsellor
Description: A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endre: a digital smoking cessation counsellor
Description: A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endre: a digital smoking cessation counsellor
Description: A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lapse management system triggered from web-page
Description: The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status every time they log on to Endre (the digital smoking cessation counsellor). Participants that report a lapse is routed to a fully automated counselling session delivered by web.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lapse management system triggered by SMS-textmessage
Description: The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status in a textmessage (SMS) sent each evening. Participants that report a lapse, receives a new SMS with a link to a fully automated counselling session delivered by web.
Study: NCT01773356

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrocapsiate
Description: Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dihydrocapsiate
Description: Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
Study: NCT03853291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PICT Workbook
Description: PICT Workbook: The PICT workbook is a 31-page manual, which includes: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set. Participants in the intervention condition also attended four weekly 30-minute sessions with an interventionist through a combination of online (video observation) and telephone coaching to go over the Workbook.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Pamphlet
Description: Pamphlet with information about pain and dementia and links to Alzheimer's Association
Study: NCT01682018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung volume reduction using the Zephyr device
Description: lung volume reduction using the Zephyr device
Study: NCT01125085

Intervention type: RADIATION
Group type: OTHER
Intervention: 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
Description: * Patients will be treated with WBRT administering a total dosage of 30 Gy in fractions of 3 Gy~* Dosimetric evaluation with 131I-L19SIP or 124I-L19SIP will be performed to assess eligibility for RIT.~* Patients eligible for RIT will receive a therapeutic dose of 131I-L19SIP.~* Total treatment duration is up to 4 weeks
Study: NCT04281628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine group:
Description: Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
Study: NCT02797678

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Powersleep
Description: Participants will receive 5 nights of stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powersleep
Description: Participants will receive 5 nights of stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Powersleep
Description: Participants will receive 5 nights of no stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Powersleep
Description: Participants will receive 5 nights of no stimulation
Study: NCT01313013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: question prompt sheet
Study: NCT02191046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: squeezable bottle
Description: nasal irrigation twice daily for 2 weeks period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: syringe 20 ml
Description: nasal irrigation twice daily for 2 weeks
Study: NCT02394184

Intervention type: PROCEDURE
Intervention: transcatheter aortic valve replacement
Study: NCT03579823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab 100 MG/ML [Humira]
Description: prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVT02 100MG/ML
Description: prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
Study: NCT00571753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid
Description: Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
Study: NCT02535754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIVE
Description: The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCS BCY
Description: The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIVE + CCS BCY
Description: The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
Study: NCT06227715

Intervention type: OTHER
Group type: OTHER
Intervention: universal adhesive

Intervention type: OTHER
Group type: OTHER
Intervention: universal adhesive

Intervention type: OTHER
Group type: OTHER
Intervention: universal adhesive
Study: NCT04422964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Obturator
Description: Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
Study: NCT04608890

Intervention type: DIAGNOSTIC_TEST
Intervention: Eye-tracking video test
Description: An eye-tracking-based test will be administered to patients. It lasts 10 minutes. It consists in several screens passing by to identify objects at a certain time by a mouse clic or touchpad.

Intervention type: DIAGNOSTIC_TEST
Intervention: Eye-tracking video test
Description: An eye-tracking-based test will be administered to patients. It lasts 10 minutes. It consists in several screens passing by to identify objects at a certain time by a mouse clic or touchpad.
Study: NCT03354052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-rTMS + Gloreha device
Description: The real rTMS will be delivered using a 8-shaped coil placed over the primary motor cortex (M1). The resting motor threshold (RMT) will be assessed at the place of the first dorsal interosseous (FDI) contralateral to the stimulated cortex. RMT of the FDI will be determined as the lowest strength of TMS needed to elicit 5 or more electromyographic responses ≥50 μV within 10 trials. Stimulation will be applied with frequency 10 Hz and intensity of 90% of RMT. Every session will last 15 minutes and includes 3000 pulses (30 trains of 10 seconds, following intertrain interval of 20 seconds). Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham-rTMS + Gloreha device
Description: The sham rTMS will be delivered using a sham stimulator. All procedures will be performed as for the real treatment. Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
Study: NCT02940236

Intervention type: OTHER
Intervention: Ultrasound
Description: Before and after patient receives oral multimodal analgesia as per standard of care, two ultrasound scans will be performed (10 minutes apart for each time element).
Study: NCT06414876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital dog
Description: The hospital dog always has a well educated dog instructor beside.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital dog
Description: The hospital dog always has a well educated dog instructor beside.
Study: NCT01872650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Qur
Description: In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
Study: NCT00549601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)
Description: Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (9.5 mg/day)
Description: Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine capsules (6 mg to 12 mg/day)
Description: Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
Study: NCT02891486

Intervention type: PROCEDURE
Intervention: Spinal surgery
Description: Elective spinal surgery performed
Study: NCT00652808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 10 mg tablet by mouth once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 500 mg capsule by mouth twice daily for 6 weeks
Study: NCT00404924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib)
Description: once daily oral tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: standard of care
Study: NCT03556397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Description: Sentinel lymph node biopsy will be performed in the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Description: Sentinel lymph node biopsy will be performed in the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Description: Sentinel lymph node biopsy will be performed in the patients
Study: NCT04028817

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo photobiomodulation
Description: the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied a placebo sublingual laser for 360 s.
Study: NCT01672138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Antrum Isolation
Description: Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Antrum Isolation
Description: Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Antrum Isolation
Description: Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scar homogenization
Description: PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scar homogenization
Description: PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-PV triggers ablation
Description: PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites
Study: NCT05250765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twistflex retainer
Description: twisted 0.0195 dead-soft coaxial wire (Respond; Ormco, Orange, Calif)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twistflex retainer
Description: twisted 0.0195 dead-soft coaxial wire (Respond; Ormco, Orange, Calif)
Study: NCT03556397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Description: Sentinel lymph node biopsy will be performed in the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Description: Axillary dissection procedure will be performed in the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Description: Axillary dissection procedure will be performed in the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Description: Axillary dissection procedure will be performed in the patients
Study: NCT00080483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone plus somatropin
Description: AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone
Description: AndroGel transdermally 5 g a day for two years
Study: NCT01476397

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control infant formula
Description: partially hydrolyzed whey infant formula consumed ad libitum throughout study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test infant formula
Description: partially hydrolyzed whey formula with probiotic
Study: NCT01197209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-REIC/Dkk-3
Description: REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
Study: NCT05250765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthoflex retainer
Description: Ortho-flextech (Reliance orthodontic products, Itasca III, USA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthoflex retainer
Description: Ortho-flextech (Reliance orthodontic products, Itasca III, USA)
Study: NCT02788266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft+composite resin
Description: treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus composite resin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft+ glass ionomer
Description: treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus resin modified glass ionomer cement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft+giomer
Description: treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus giomer
Study: NCT03024996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV infusion q3w

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to atezolizumab q3w
Study: NCT03499561

Intervention type: DIAGNOSTIC_TEST
Intervention: urine analysis
Description: Intervention is (urine analysis ): of a mid stream urine sample will be taken

Intervention type: DIAGNOSTIC_TEST
Intervention: urine analysis
Description: Intervention is (urine analysis ): of a mid stream urine sample will be taken

Intervention type: DIAGNOSTIC_TEST
Intervention: urine analysis
Description: Intervention is (urine analysis ): of a mid stream urine sample will be taken
Study: NCT03292445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immune tolerance after kidney transplant
Description: Induction of immune tolerance after kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and anti-thymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no kidney rejection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor blood stem cells and T cells
Description: Immune tolerance after kidney transplantation resulting from mixed blood cells chimerism will be induced by donor blood stem cells and T cells given to the kidney recipient. Donor cells will be collected by apheresis after mobilization of blood stem cells from bone marrow 6-8 weeks before kidney transplant. Collected cells will undergo CD34 selection to recover \>10 million donor blood stem cells/kg of patient weight to be combined with up to 150 million donor T cells/kg for transfusion soon after kidney transplant. The IND for this study covers the infusion of donor blood stem cells.